

Nagy A Habib

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9536611/publications.pdf>

Version: 2024-02-01

100
papers

4,639
citations

117625

34
h-index

106344

65
g-index

103
all docs

103
docs citations

103
times ranked

5874
citing authors

#	ARTICLE	IF	CITATIONS
1	Endoscopically applied radiofrequency ablation appears to be safe in the treatment of malignant biliary obstruction. <i>Gastrointestinal Endoscopy</i> , 2011, 73, 149-153.	1.0	289
2	Characterization and Clinical Application of Human CD34 ⁺ Stem/Progenitor Cell Populations Mobilized into the Blood by Granulocyte Colony-Stimulating Factor. <i>Stem Cells</i> , 2006, 24, 1822-1830.	3.2	267
3	New Technique for Liver Resection Using Heat Coagulative Necrosis. <i>Annals of Surgery</i> , 2002, 236, 560-563.	4.2	252
4	Recent Development of Augmented Reality in Surgery: A Review. <i>Journal of Healthcare Engineering</i> , 2017, 2017, 1-9.	1.9	244
5	Autologous Infusion of Expanded Mobilized Adult Bone Marrow-Derived CD34 ⁺ Cells Into Patients With Alcoholic Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2008, 103, 1952-1958.	0.4	195
6	Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors. <i>World Journal of Gastrointestinal Surgery</i> , 2015, 7, 52.	1.5	194
7	Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug. <i>Molecular Therapy</i> , 2020, 28, 1759-1771.	8.2	177
8	MicroRNAs Cooperatively Inhibit a Network of Tumor Suppressor Genes to Promote Pancreatic Tumor Growth and Progression. <i>Gastroenterology</i> , 2014, 146, 268-277.e18.	1.3	141
9	Non-alcoholic fatty liver disease: A sign of systemic disease. <i>Metabolism: Clinical and Experimental</i> , 2017, 72, 94-108.	3.4	132
10	Intra-Arterial Immunoselected CD34 ⁺ Stem Cells for Acute Ischemic Stroke. <i>Stem Cells Translational Medicine</i> , 2014, 3, 1322-1330.	3.3	131
11	Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. <i>Cancer Gene Therapy</i> , 2002, 9, 254-259.	4.6	120
12	Partial characterization of a cDNA for human stearoyl-CoA desaturase and changes in its mRNA expression in some normal and malignant tissues. <i>International Journal of Cancer</i> , 1994, 57, 348-352.	5.1	119
13	Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden. <i>Oncotarget</i> , 2018, 9, 19006-19013.	1.8	116
14	E1B-Deleted Adenovirus (dl1520) Gene Therapy for Patients with Primary and Secondary Liver Tumors. <i>Human Gene Therapy</i> , 2001, 12, 219-226.	2.7	113
15	Analysis of Endoscopic Radiofrequency Ablation of Biliary Malignant Strictures in Pancreatic Cancer Suggests Potential Survival Benefit. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3449-3455.	2.3	105
16	Safety and Efficacy of Radiofrequency Ablation in the Management of Unresectable Bile Duct and Pancreatic Cancer: A Novel Palliation Technique. <i>Journal of Oncology</i> , 2013, 2013, 1-5.	1.3	104
17	Will Nanotechnology Bring New Hope for Gene Delivery?. <i>Trends in Biotechnology</i> , 2017, 35, 434-451.	9.3	97
18	microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis. <i>European Journal of Cancer</i> , 2015, 51, 1389-1404.	2.8	94

#	ARTICLE	IF	CITATIONS
19	Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis <i>in vivo</i> . <i>Hepatology</i> , 2014, 59, 216-227.	7.3	92
20	MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP β , in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial. <i>Clinical Cancer Research</i> , 2020, 26, 3936-3946.	7.0	86
21	Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer. <i>Molecular Therapy</i> , 2017, 25, 2705-2714.	8.2	76
22	Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA) of the Pancreas in a Porcine Model. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-6.	1.5	74
23	Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 6, 80-88.	5.1	65
24	Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer. <i>Oncogene</i> , 2018, 37, 3216-3228.	5.9	60
25	Integrated molecular analysis to investigate the role of microRNAs in pancreatic tumour growth and progression. <i>Lancet, The</i> , 2015, 385, S37.	13.7	54
26	Targeted Delivery of C/EBP β -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo. <i>Molecular Therapy</i> , 2016, 24, 1106-1116.	8.2	53
27	Cannabinoids in the landscape of cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2507-2534.	2.5	53
28	Developing small activating RNA as a therapeutic: current challenges and promises. <i>Therapeutic Delivery</i> , 2019, 10, 151-164.	2.2	49
29	Liver Activation of Hepatocellular Nuclear Factor-4 β by Small Activating RNA Rescues Dyslipidemia and Improves Metabolic Profile. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 19, 361-370.	5.1	47
30	Upregulation of C/EBP β Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5961-5978.	7.0	47
31	Detection of adenovirus and initiation of apoptosis in hepatocellular carcinoma cells after ad-p53 treatment. <i>Hepatology</i> , 2000, 31, 885-889.	7.3	44
32	Impact of radiofrequency assisted hepatectomy for reduction of transfusion requirements. <i>American Journal of Surgery</i> , 2007, 193, 143-148.	1.8	42
33	PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma. <i>BMC Cancer</i> , 2021, 21, 301.	2.6	42
34	Oncological Outcomes of Major Liver Resection Following Portal Vein Embolization: A Systematic Review and Meta-analysis. <i>Annals of Surgical Oncology</i> , 2016, 23, 3709-3717.	1.5	38
35	An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFR β Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 14, 131-141.	5.1	38
36	Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study. <i>British Journal of Cancer</i> , 2018, 119, 815-822.	6.4	35

#	ARTICLE	IF	CITATIONS
37	Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma. <i>Current Pharmaceutical Biotechnology</i> , 2018, 19, 611-621.	1.6	31
38	Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis. <i>Hpb</i> , 2019, 21, 773-783.	0.3	31
39	Assessment of growth inhibition and morphological changes in in vitro and in vivo hepatocellular carcinoma models post treatment with dl1520 adenovirus. <i>Cancer Gene Therapy</i> , 2002, 9, 414-420.	4.6	30
40	Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis. <i>Acta Pharmaceutica Sinica B</i> , 2015, 5, 194-200.	12.0	30
41	C/EBP β Short-Activating RNA Suppresses Metastasis of Hepatocellular Carcinoma through Inhibiting EGFR/ β -Catenin Signaling Mediated EMT. <i>PLoS ONE</i> , 2016, 11, e0153117.	2.5	30
42	Gene Expression Profile Changes After Short-activating RNA-mediated Induction of Endogenous Pluripotency Factors in Human Mesenchymal Stem Cells. <i>Molecular Therapy - Nucleic Acids</i> , 2012, 1, e35.	5.1	28
43	Blind SELEX Approach Identifies RNA Aptamers That Regulate EMT and Inhibit Metastasis. <i>Molecular Cancer Research</i> , 2017, 15, 811-820.	3.4	24
44	Mechanisms involved in the activation of C/EBP β by small activating RNA in hepatocellular carcinoma. <i>Oncogene</i> , 2019, 38, 3446-3457.	5.9	24
45	Targeted Delivery of C/EBP β -saRNA by RNA Aptamers Shows Anti-tumor Effects in a Mouse Model of Advanced PDAC. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 18, 142-154.	5.1	23
46	Endoscopic ultrasound-guided lymph node ablation with a novel radiofrequency ablation probe: feasibility study in an acute porcine model. <i>Endoscopy</i> , 2014, 46, 411-415.	1.8	22
47	Endoscopic Radiofrequency Ablation in Colorectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 355-358.	1.3	21
48	Positive Immuno-Modulation Following Radiofrequency Assisted Liver Resection in Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2019, 8, 385.	2.4	21
49	Adenovirus replication-competent vectors (KD1, KD3) complement the cytotoxicity and transgene expression from replication-defective vectors (Ad-GFP, Ad-Luc). <i>Cancer Gene Therapy</i> , 2002, 9, 651-654.	4.6	20
50	A perspective on non-catalytic Src homology (SH) adaptor signalling proteins. <i>Cellular Signalling</i> , 2012, 24, 388-392.	3.6	20
51	Endogenous aldehyde accumulation generates genotoxicity and exhaled biomarkers in esophageal adenocarcinoma. <i>Nature Communications</i> , 2021, 12, 1454.	12.8	20
52	Autologous Bone Marrow Stem Cells in the Treatment of Chronic Liver Disease. <i>International Journal of Hepatology</i> , 2012, 2012, 1-7.	1.1	19
53	Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies. <i>Oncotarget</i> , 2016, 7, 28556-28569.	1.8	19
54	Impact of cavitron ultrasonic surgical aspirator (CUSA) and bipolar radiofrequency device (Habib-4X) based hepatectomy for hepatocellular carcinoma on tumour recurrence and disease-free survival. <i>Oncotarget</i> , 2017, 8, 93644-93654.	1.8	16

#	ARTICLE	IF	CITATIONS
55	Total vascular exclusion for liver resections: Pros and cons. , 1999, 72, 50-55.		15
56	Enhancement of immunogenicity of tumor cells by cotransfection with genes encoding antisense insulin-like growth factor-1 and B7.1 molecules. <i>Cancer Gene Therapy</i> , 2000, 7, 456-465.	4.6	15
57	Limitations in Clinical Translation of Nanoparticle-Based Gene Therapy. <i>Trends in Biotechnology</i> , 2017, 35, 1124-1125.	9.3	15
58	RNA Activation – A Novel Approach to Therapeutically Upregulate Gene Transcription. <i>Molecules</i> , 2021, 26, 6530.	3.8	15
59	The effect of mechanically enhancing portal venous inflow on hepatic oxygenation, microcirculation, and function in a rabbit model with extensive hepatic fibrosis. <i>Hepatology</i> , 1999, 30, 46-52.	7.3	14
60	Study to evaluate the immunomodulatory effects of radiofrequency ablation compared to surgical resection for liver cancer. <i>Journal of Cancer</i> , 2018, 9, 3187-3195.	2.5	14
61	Immunological combination treatment holds the key to improving survival in pancreatic cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2897-2911.	2.5	14
62	Recent Advances: The Imbalance of Immune Cells and Cytokines in the Pathogenesis of Hepatocellular Carcinoma. <i>Diagnostics</i> , 2020, 10, 338.	2.6	14
63	Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice. <i>Molecular Therapy</i> , 2019, 27, 999-1016.	8.2	13
64	Radiofrequency combined with immunomodulation for hepatocellular carcinoma: State of the art and innovations. <i>World Journal of Gastroenterology</i> , 2020, 26, 2040-2048.	3.3	13
65	Unique-region phosphorylation targets LynA for rapid degradation, tuning its expression and signaling in myeloid cells. <i>ELife</i> , 2019, 8, .	6.0	13
66	Microsatellite Instability And Allelic Imbalance In Primary And Secondary Colorectal Cancer. <i>Australian and New Zealand Journal of Surgery</i> , 2000, 70, 587-592.	0.2	12
67	Augmented portal flow in the isolated perfused cirrhotic rat liver: a haemodynamic and morphological study. <i>Clinical Science</i> , 1993, 84, 185-192.	4.3	11
68	The cytotoxic effect of E1B 55-kDa mutant adenovirus on human hepatocellular carcinoma cell lines. <i>Cancer Gene Therapy</i> , 2001, 8, 333-341.	4.6	10
69	Radiofrequency-assisted liver resection: Technique and results. <i>Surgical Oncology</i> , 2018, 27, 415-420.	1.6	10
70	MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9168.	4.1	10
71	Small Activating RNA Modulation of the G Protein-Coupled Receptor for Cancer Treatment. <i>Advanced Science</i> , 2022, 9, .	11.2	10
72	Identification of Cellular Targets of MicroRNA-181a in HepG2 Cells: A New Approach for Functional Analysis of MicroRNAs. <i>PLoS ONE</i> , 2015, 10, e0123167.	2.5	9

#	ARTICLE	IF	CITATIONS
73	A systematic review on radiofrequency assisted laparoscopic liver resection: Challenges and window to excel. <i>Surgical Oncology</i> , 2017, 26, 296-304.	1.6	9
74	Immunological Basis of Genesis of Hepatocellular Carcinoma: Unique Challenges and Potential Opportunities through Immunomodulation. <i>Vaccines</i> , 2020, 8, 247.	4.4	9
75	Intravascular Micropump for Augmented Liver Perfusion: First In Vivo Experience. <i>Artificial Organs</i> , 2001, 25, 392-394.	1.9	8
76	The use of radiofrequency ablation in pancreatic cancer in the midst of the dawn of immuno-oncology. <i>Medical Oncology</i> , 2018, 35, 151.	2.5	8
77	Exploiting Human CD34+ Stem Cellâ€“conditioned Medium for Tissue Repair. <i>Molecular Therapy</i> , 2014, 22, 149-159.	8.2	7
78	No difference in mortality among ALPPS, two-staged hepatectomy, and portal vein embolization/ligation: A systematic review by updated traditional and network meta-analyses. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2020, 19, 411-419.	1.3	7
79	Treatment of Liver Cancer by C/EBPA saRNA. <i>Advances in Experimental Medicine and Biology</i> , 2017, 983, 189-194.	1.6	7
80	The use of hypothermia and circulatory arrest to control intraoperative bleeding from the inferior vena cava. <i>Surgery Today</i> , 1996, 26, 217-218.	1.5	6
81	Preliminary results of a first-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-Î± in patients with advanced liver cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2509-2509.	1.6	6
82	Can we predict long-term survival in resectable pancreatic ductal adenocarcinoma?. <i>Oncotarget</i> , 2019, 10, 696-706.	1.8	6
83	Emerging In Vitro 3D Tumour Models in Nanoparticle-Based Gene and Drug Therapy. <i>Trends in Biotechnology</i> , 2018, 36, 477-480.	9.3	4
84	The journey of radiofrequency-assisted liver resection. <i>Surgical Oncology</i> , 2018, 27, A16-A18.	1.6	3
85	Image-Guided Percutaneous Pancreatic Duct Drainage: A 10-Year Observational Study. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 1075-1080.e2.	0.5	3
86	Radiofrequency assisted pancreaticoduodenectomy for palliative surgical resection of locally advanced pancreatic adenocarcinoma. <i>Oncotarget</i> , 2018, 9, 15732-15739.	1.8	3
87	Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. , 0, .		2
88	First-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-Î± in patients with advanced liver cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS2612-TPS2612.	1.6	2
89	Haemostasis in Liver Surgery. , 2007, , 153-164.		2
90	Radiofrequency-Assisted Liver Resection. , 2008, , 551-567.		2

#	ARTICLE	IF	CITATIONS
91	Technical Development of a New Semispherical Radiofrequency Bipolar Device (RONJA):<i>Ex Vivo</i>and<i>In Vivo</i>Studies. BioMed Research International, 2014, 2014, 1-7.	1.9	1
92	Immunomodulatory Changes Following Isolated RF Ablation in Colorectal Liver Metastases: A Case Report. Medicines (Basel, Switzerland), 2019, 6, 56.	1.4	1
93	Abstract 3856: MTLCEBPA, a drug candidate for hepatocellular-carcinoma enhances efficacy of Sorafenib. , 2019, , .		1
94	Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2020, 38, 4601-4601.	1.6	1
95	The Isolation and Characterisation of CD34 Positive Cells from the Human Adult Liver. Clinical Science, 2003, 104, 21P-21P.	0.0	0
96	The Use of Mesenchymal Stem Cells for Bone and Cartilage Repair. , 2008, , 269-294.		0
97	The Meritocracy of Stem Cells for Therapy. , 2008, , 1-5.		0
98	Adult Human Stem Cell Therapy for Ischaemic Stroke. , 2008, , 181-197.		0
99	Liver Repair. , 2008, , 619-631.		0
100	Targeting chromatin: Transcriptional gene activation (saRNA). , 2022, , 3-16.		0